149 related articles for article (PubMed ID: 33609557)
1. The DNA replication regulator MCM6: An emerging cancer biomarker and target.
Zeng T; Guan Y; Li YK; Wu Q; Tang XJ; Zeng X; Ling H; Zou J
Clin Chim Acta; 2021 Jun; 517():92-98. PubMed ID: 33609557
[TBL] [Abstract][Full Text] [Related]
2. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
3.
Hou L; Zeng X; Li X; Zhao C; Zou J; Li Y; Liu G
Comput Math Methods Med; 2022; 2022():3116303. PubMed ID: 35720029
[TBL] [Abstract][Full Text] [Related]
4. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
[TBL] [Abstract][Full Text] [Related]
5. GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer.
Zheng Y; Shi Y; Yu S; Han Y; Kang K; Xu H; Gu H; Sang X; Chen Y; Wang J
Anal Cell Pathol (Amst); 2019; 2019():1038069. PubMed ID: 32082966
[TBL] [Abstract][Full Text] [Related]
6. The impact of MCM6 on hepatocellular carcinoma in a Southern Chinese Zhuang population.
Jia W; Xie L; Wang X; Zhang Q; Wei B; Li H; Qin S; Chen S; Liu J; Tan Y; Zheng S; Liang X; Yang X
Biomed Pharmacother; 2020 Jul; 127():110171. PubMed ID: 32403044
[TBL] [Abstract][Full Text] [Related]
7. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
Aging (Albany NY); 2021 Feb; 13(4):4962-4975. PubMed ID: 33668040
[TBL] [Abstract][Full Text] [Related]
8. MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.
Gao C; Li J; Zeng F; Wang L; Chen K; Chen D; Hong J; Qu C
Carcinogenesis; 2023 Jun; 44(4):279-290. PubMed ID: 37185675
[TBL] [Abstract][Full Text] [Related]
9. MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target.
Wang Y; Chen H; Liu W; Yan H; Zhang Y; Cheung AHK; Zhang J; Chen B; Liang L; Zhou Z; Wong CC; Wu WKK; Chan MWY; Cheng ASL; Ma BBY; Yu J; Lo KW; To KF; Kang W
Theranostics; 2022; 12(15):6509-6526. PubMed ID: 36185598
[No Abstract] [Full Text] [Related]
10. High MCM6 expression promotes proliferation and correlates with poor prognosis in triple-negative breast cancer.
Zhang H; Lin YD; Zhuang MX; Zhu L; Yu Y; Chen XG; Wang QS; Lin MB
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2906-2922. PubMed ID: 38639528
[TBL] [Abstract][Full Text] [Related]
11. Minichromosome maintenance protein family member 6 mediates hepatocellular carcinoma progression by recruiting UBE3A to induce P53 ubiquitination.
Zhang X; Bian S; Ni Y; Zhou L; Yang C; Zhang C; Sun X; Xu N; Xu S; Wang Y; Gu S; Zheng W
Int J Biol Macromol; 2023 Sep; 248():125854. PubMed ID: 37460074
[TBL] [Abstract][Full Text] [Related]
12. High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.
Jang NR; Baek J; Ko Y; Song PH; Gu MJ
In Vivo; 2021; 35(1):299-306. PubMed ID: 33402477
[TBL] [Abstract][Full Text] [Related]
13. A novel cell-cycle-regulated interaction of the Bloom syndrome helicase BLM with Mcm6 controls replication-linked processes.
Shastri VM; Subramanian V; Schmidt KH
Nucleic Acids Res; 2021 Sep; 49(15):8699-8713. PubMed ID: 34370039
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of MCM6 predicts poor survival in patients with glioma.
Cai HQ; Cheng ZJ; Zhang HP; Wang PF; Zhang Y; Hao JJ; Wang MR; Wan JH
Hum Pathol; 2018 Aug; 78():182-187. PubMed ID: 29753008
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome Maintenance Complex is Required for Checkpoint Kinase 2 Chromatin Loading and its Phosphorylation to DNA Damage Response in SCC-4 Cells.
Li L; Feng Y; Luo R
Protein Pept Lett; 2017; 24(3):223-228. PubMed ID: 27964702
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
Wang F; Xie C; Zhao W; Deng Z; Yang H; Fang Q
Clin Exp Med; 2017 Feb; 17(1):33-43. PubMed ID: 26433964
[TBL] [Abstract][Full Text] [Related]
17. MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.
Lei Z; Wang P; Jia DQ; Li LL; Wu YP; Yang Y; Pan GQ
Front Biosci (Landmark Ed); 2023 Aug; 28(8):128. PubMed ID: 37664925
[TBL] [Abstract][Full Text] [Related]
18. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis.
Wang Y; He D; Yang L; Wen B; Dai J; Zhang Q; Kang J; He W; Ding Q; He D
Biochem Biophys Res Commun; 2015 Jul; 463(3):458-65. PubMed ID: 26043685
[TBL] [Abstract][Full Text] [Related]
19. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.
Hotton J; Agopiantz M; Leroux A; Charra-Brunaud C; Marie B; Busby-Venner H; Morel O; Guéant JL; Vignaud JM; Battaglia-Hsu SF; Gauchotte G
Virchows Arch; 2018 Apr; 472(4):623-633. PubMed ID: 29243125
[TBL] [Abstract][Full Text] [Related]
20. MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.
Gu Y; Hu X; Liu X; Cheng C; Chen K; Wu Y; Wu Z
BMC Cancer; 2021 Jul; 21(1):784. PubMed ID: 34233647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
